A recent study by Booz Allen Hamilton in the US finds that drug companies are mostly meeting their post-marketing surveillance (PMS) obligations in the US. Dow Jones Newswires reports that 80 per cent of the PMS studies that Booz reviewed were either meeting their deadlines, were submitted to the FDA for review, or were already … Continue reading Post-marketing surveillance : Does anyone know?
The French have an adage - 'plus ca change, plus c'est la meme chose.' The more things change, the more they remain the same. I can't help wondering whether that is going to happen to Wockhardt's pharma division Merind. This was the vehicle through which US-based Merck & Co., used to operate in India till … Continue reading Merind : Will the wheel turn full circle?